Compare Amgen, Inc. (AMGN) vs Enphase Energy Inc (ENPH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Enphase Energy Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Enphase Energy Inc trades at $44.05 (market cap $5.91B). The key difference: Amgen, Inc. is far larger — about 33.2× Enphase Energy Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Enphase Energy Inc pays none. Which is the better fit depends on your goals.
| AMGN | ENPH | |
|---|---|---|
Market Cap | $196.12B | $5.91B |
Sector | Health | Technology |
52-Week High | $388.16 | $72.33 |
52-Week Low | $271.18 | $26.12 |
Enterprise Value | $241.41B | $5.56B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
ENPH trades at $44.83, down 0.13% with a bearish technical signal. Recent earnings beats (Q1 2026 EPS $0.47 vs. $0.43 expected) contrast with declining revenue trends (2025: $1.47B vs. 2023 peak $2.3B). Analyst consensus is mixed (40% Buy, 51% Hold) with a $42.79 price target below current levels. News highlights product launches like IQ9N microinverters and Open Compute Project membership, aiming to leverage AI data center demand.
Outlook remains cautious due to revenue volatility and high valuation (P/E 44.39). Opportunities exist in new product adoption and regulatory tailwinds (FCC inverter import ban proposal, Reuters June 2026), but risks include solar sector competition and execution challenges. Institutional sentiment is neutral with modest net cash flow of $10.20M in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →
